COVID-19. COVID-19
Conditions
Interventions
Intervention 1: Intervention group: Patients admitted following COVID-19 receive 200 milligrams of Fenofibrate capsule by Sobhan Darou including one 100 milligram capsule every 12 hours orally during
Sponsors
Artesh University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age more than 18 years Confirmed diagnosis of COVID-19 with RT-PCR Hospitalization Symptom onset lower than 10 days
Exclusion criteria
Exclusion criteria: Pregnancy, breastfeeding Known hypersensitivity to fibrate agents History of Fenofibrate treatment Previous treatment with warfarin, ciclosporin, tacrolimus, and atorvastatin more than 40 milligrams (mg) daily History of liver diseases, and hypothyroidism
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mortality. Timepoint: From admission to 3 months after discharge. Method of measurement: Electronic records and contacting patient after discharge.;ICU admission. Timepoint: From hospitalization to discharge. Method of measurement: Patient status by electronic records. | — |
Secondary
| Measure | Time frame |
|---|---|
| Hospitalization days. Timepoint: At discharge. Method of measurement: Patient electronic records.;ICU stay. Timepoint: At dischagre. Method of measurement: Patient electronic records.;Mechanical ventilaton. Timepoint: At discharge. Method of measurement: Need for mechanical ventilation by reviewing electronic records. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFarbod Hatami
Birjand University of Medical Sciences
Outcome results
None listed